The company will use the capital to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity General Proximity's proprietary OmniTAC platform enables the precise and selective modification of...
Read More Details
Finally We wish PressBee provided you with enough information of ( General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' Targets )
Also on site :